Navamepent
Navamepent is a synthetic analogue of the endogenous fatty acid resolvin E1, a member of the specialized pro-resolving mediators. Navamepent is presumed to act as an agonist of the CMKLR1 receptor in a manner similar to resolvin E1.
It was developed as a topical ophthalmic formulation to promote recovery from eye inflammation and advanced to Phase II clinical trials, but was not pursued further.